SCHEMBL6743454

SCHEMBL6743454

CC(C)n1ncc2ccc(CCN(C)C)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.39
KMO O15229 1/20 0.39
HDAC8 Q9BY41 1/20 0.38
TERT O14746 1/20 0.38
TAAR1 Q96RJ0 6/20 0.37
CHRNA7 P36544 1/20 0.36
EGFR P00533 1/20 0.35
ITK Q08881 1/20 0.35
PTGER3 P43115 1/20 0.35
NOS1 P29475 2/20 0.34
NOS2 P35228 1/20 0.34
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
CYP1A2 P05177 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C19 P33261 1/20 0.34
KMT2A Q03164 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
PDE1A P54750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6740845 0.86 HRH3 (0.40) HRH3KMOHDAC8PTGER3SIGMAR1
SCHEMBL28264487 0.82 BPTF (0.44) HRH3TERTTAAR1CHRNA7HTR1A
SCHEMBL12327554 0.80 HDAC8 (0.53) KMOHDAC8PTGER3CYP1A2PDE1A
SCHEMBL20942425 0.79 HDAC8 (0.43) KMOHDAC8PTGER3PDE1APDE1B
SCHEMBL30174486 0.79 KMO (0.45) KMOHDAC8EGFRPTGER3PDE1A
SCHEMBL15687398 0.79 KMO (0.45) KMOHDAC8EGFRPTGER3PDE1A
SCHEMBL19966783 0.77 KMO (0.40) KMOHDAC8PTGER3PDE1APDE1B
SCHEMBL6746545 0.76 SIGMAR1 (0.48) HRH3ALDH1A1CYP1A2SIGMAR1HTR7
SCHEMBL6744650 0.75 PTGER3 (0.41) KMOHDAC8PTGER3PDE1APDE1B
SCHEMBL6740869 0.75 KMO (0.38) KMOHDAC8PTGER3PDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US claimed
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-08-26 US disclosed
US-6716837-B1 INDOLE AND INDAZOLE COMPOUNDS NPS ALLELIX BIOPHARMACEUTICALS, INC. (CA) 2004-04-06 US disclosed
EP-1196380-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2002-04-17 EP disclosed
WO-2001005758-A2 INDOLES AND INDAZOLES FOR THE TREATMENT OF MIGRAINE NPS ALLELIX CORP. (CA) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167158-A1 Heterocyclic compounds for the treatment of migraine SCN7A, CNR2, HTR7 HRH3 21/4885KMO 453/4885HDAC8 428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.